TocilizumabV1, Main, Exploration, bibRecord, 000D95

Cytokine release syndrome. Reviewing a new entity in the intensive care unit.

Identifieur interne : 000D95 ( Main/Exploration ); précédent : 000D94; suivant : 000D96

Cytokine release syndrome. Reviewing a new entity in the intensive care unit.

Auteurs : Alejandra García Roche [Espagne] ; Cándido Díaz Lagares [Espagne] ; Elena Élez [Espagne] ; Ricard Ferrer Roca [Espagne]

Source :

Medicina intensiva [ 1578-6749 ] ; 2019.

RBID : pubmed:30922608

Abstract

Immunotherapy seeks to harness the power of the immune system to eradicate malignant tissues. Despite impressive therapeutic success, however, it can be accompanied by severe adverse effects such as cytokine release syndrome (CRS). These therapies cause the release of a great amount of cytokines, with IL-6 playing a central role, that can potentially lead to multiple organ dysfunction. The diagnosis is based on the presence of compatible clinical symptoms, elevated biomarkers and recent treatment with a biological agent. Mild cases can be managed through symptomatic treatment and fluids, while more severe episodes may need supportive therapy and specific care with the anti-IL-6 receptor monoclonal antibody tocilizumab. Although corticosteroids are also effective, they suppress T-cell activity, and so should only be considered as second line therapy or in cases of severe neurological involvement, since tocilizumab does not cross the blood-brain barrier. Cytokine release syndrome generally has a good prognosis, often being reversible and with a good response to specific treatment. Despite possible concerns about the admission of such patients (mainly with advanced oncological disease), we consider that the Intensive Care Unit should remain an option, since these individuals present a potentially reversible drug-related adverse event and are being treated with a new drug that could change the prognosis of the disorder. Intensive care medicine will become a key component in the management of the complications of modern cancer therapies, dealing with patients presenting an overactive immune system producing organ dysfunction while also trying to maintain treatment efficacy. This is the new paradigm.

DOI: 10.1016/j.medin.2019.01.009
PubMed: 30922608

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cytokine release syndrome. Reviewing a new entity in the intensive care unit.</title>
<author><name sortKey="Garcia Roche, Alejandra" sort="Garcia Roche, Alejandra" uniqKey="Garcia Roche A" first="Alejandra" last="García Roche">Alejandra García Roche</name>
<affiliation wicri:level="3"><nlm:affiliation>Intensive Care Department. SODIR Research Group. Vall d́Hebron University Hospital, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Intensive Care Department. SODIR Research Group. Vall d́Hebron University Hospital, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Diaz Lagares, Candido" sort="Diaz Lagares, Candido" uniqKey="Diaz Lagares C" first="Cándido" last="Díaz Lagares">Cándido Díaz Lagares</name>
<affiliation wicri:level="3"><nlm:affiliation>Intensive Care Department. SODIR Research Group. Vall d́Hebron University Hospital, Barcelona, España. Electronic address: c.diaz@vhebron.net.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Intensive Care Department. SODIR Research Group. Vall d́Hebron University Hospital, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Elez, Elena" sort="Elez, Elena" uniqKey="Elez E" first="Elena" last="Élez">Elena Élez</name>
<affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department. VHIO. Vall d́Hebron University Hospital, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Medical Oncology Department. VHIO. Vall d́Hebron University Hospital, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferrer Roca, Ricard" sort="Ferrer Roca, Ricard" uniqKey="Ferrer Roca R" first="Ricard" last="Ferrer Roca">Ricard Ferrer Roca</name>
<affiliation wicri:level="3"><nlm:affiliation>Intensive Care Department. SODIR Research Group. Vall d́Hebron University Hospital, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Intensive Care Department. SODIR Research Group. Vall d́Hebron University Hospital, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:30922608</idno>
<idno type="pmid">30922608</idno>
<idno type="doi">10.1016/j.medin.2019.01.009</idno>
<idno type="wicri:Area/PubMed/Corpus">000436</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000436</idno>
<idno type="wicri:Area/PubMed/Curation">000436</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000436</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000514</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000514</idno>
<idno type="wicri:Area/Ncbi/Merge">001E77</idno>
<idno type="wicri:Area/Ncbi/Curation">001E77</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001E77</idno>
<idno type="wicri:Area/Main/Merge">000D95</idno>
<idno type="wicri:Area/Main/Curation">000D95</idno>
<idno type="wicri:Area/Main/Exploration">000D95</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cytokine release syndrome. Reviewing a new entity in the intensive care unit.</title>
<author><name sortKey="Garcia Roche, Alejandra" sort="Garcia Roche, Alejandra" uniqKey="Garcia Roche A" first="Alejandra" last="García Roche">Alejandra García Roche</name>
<affiliation wicri:level="3"><nlm:affiliation>Intensive Care Department. SODIR Research Group. Vall d́Hebron University Hospital, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Intensive Care Department. SODIR Research Group. Vall d́Hebron University Hospital, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Diaz Lagares, Candido" sort="Diaz Lagares, Candido" uniqKey="Diaz Lagares C" first="Cándido" last="Díaz Lagares">Cándido Díaz Lagares</name>
<affiliation wicri:level="3"><nlm:affiliation>Intensive Care Department. SODIR Research Group. Vall d́Hebron University Hospital, Barcelona, España. Electronic address: c.diaz@vhebron.net.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Intensive Care Department. SODIR Research Group. Vall d́Hebron University Hospital, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Elez, Elena" sort="Elez, Elena" uniqKey="Elez E" first="Elena" last="Élez">Elena Élez</name>
<affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department. VHIO. Vall d́Hebron University Hospital, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Medical Oncology Department. VHIO. Vall d́Hebron University Hospital, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferrer Roca, Ricard" sort="Ferrer Roca, Ricard" uniqKey="Ferrer Roca R" first="Ricard" last="Ferrer Roca">Ricard Ferrer Roca</name>
<affiliation wicri:level="3"><nlm:affiliation>Intensive Care Department. SODIR Research Group. Vall d́Hebron University Hospital, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Intensive Care Department. SODIR Research Group. Vall d́Hebron University Hospital, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Medicina intensiva</title>
<idno type="eISSN">1578-6749</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Immunotherapy seeks to harness the power of the immune system to eradicate malignant tissues. Despite impressive therapeutic success, however, it can be accompanied by severe adverse effects such as cytokine release syndrome (CRS). These therapies cause the release of a great amount of cytokines, with IL-6 playing a central role, that can potentially lead to multiple organ dysfunction. The diagnosis is based on the presence of compatible clinical symptoms, elevated biomarkers and recent treatment with a biological agent. Mild cases can be managed through symptomatic treatment and fluids, while more severe episodes may need supportive therapy and specific care with the anti-IL-6 receptor monoclonal antibody tocilizumab. Although corticosteroids are also effective, they suppress T-cell activity, and so should only be considered as second line therapy or in cases of severe neurological involvement, since tocilizumab does not cross the blood-brain barrier. Cytokine release syndrome generally has a good prognosis, often being reversible and with a good response to specific treatment. Despite possible concerns about the admission of such patients (mainly with advanced oncological disease), we consider that the Intensive Care Unit should remain an option, since these individuals present a potentially reversible drug-related adverse event and are being treated with a new drug that could change the prognosis of the disorder. Intensive care medicine will become a key component in the management of the complications of modern cancer therapies, dealing with patients presenting an overactive immune system producing organ dysfunction while also trying to maintain treatment efficacy. This is the new paradigm.</div>
</front>
</TEI>
<affiliations><list><country><li>Espagne</li>
</country>
<region><li>Catalogne</li>
</region>
<settlement><li>Barcelone</li>
</settlement>
</list>
<tree><country name="Espagne"><region name="Catalogne"><name sortKey="Garcia Roche, Alejandra" sort="Garcia Roche, Alejandra" uniqKey="Garcia Roche A" first="Alejandra" last="García Roche">Alejandra García Roche</name>
</region>
<name sortKey="Diaz Lagares, Candido" sort="Diaz Lagares, Candido" uniqKey="Diaz Lagares C" first="Cándido" last="Díaz Lagares">Cándido Díaz Lagares</name>
<name sortKey="Elez, Elena" sort="Elez, Elena" uniqKey="Elez E" first="Elena" last="Élez">Elena Élez</name>
<name sortKey="Ferrer Roca, Ricard" sort="Ferrer Roca, Ricard" uniqKey="Ferrer Roca R" first="Ricard" last="Ferrer Roca">Ricard Ferrer Roca</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D95 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D95 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:30922608
   |texte=   Cytokine release syndrome. Reviewing a new entity in the intensive care unit.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:30922608" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a TocilizumabV1

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

Serveur d'exploration Tocilizumab

Cytokine release syndrome. Reviewing a new entity in the intensive care unit.

Cytokine release syndrome. Reviewing a new entity in the intensive care unit.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Tocilizumab
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.